Synairgen shares are up 14% in 1 month. Would I buy now?

Why have Synairgen shares rallied recently? Nadia Yaqub takes a closer look at the reasons behind this and whether she’d buy the stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Coronavirus written newspaper close up shot to the text.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Synairgen (LSE: SNG) shares are up 14% over the past month. The stock first came onto my radar in December and I’ve been watching it ever since. I’ve written about the stock a few times and I think its worth another update given the share price rise.

What makes Synairgen shares different?

I think a quick reminder of what makes Synairgen shares different from the other pharmaceutical stocks is worth a mention.

Large drug companies such as Pfizer and AstraZeneca have created vaccines for Covid-19. What Synairgen is doing is creating a treatment, called SNG001. This means that if anyone develops Covid-19, SNG001 could be used to treat it.

In a nutshell, Synairgen’s treatment should be effective where vaccines aren’t. It could also prove useful in the case the virus mutates to the point where vaccines become less effective.

I must highlight that it’s still early days for SNG001. The treatment is being trialed and hasn’t yet received regulatory sign-off to be used when treating Covid-19. But I think things look promising for Synairgen shares.

What’s the story so far?

I’ve been watching the stock since December and a lot has happened since then. SNG001 has successfully completed Phase I and II trials, which involves using the treatment on a sample of hospitalised patients and assessing the results. Just because it has completed the first two phases, of course, doesn’t guarantee it’ll pass Phase III. 

I reckon the recent positive news flow on Synairgen shares has boosted the price. In December, the AIM-listed company announced that it would conduct further trials in the US. But this wasn’t the best part. Synairgen also announced that the US regulator, FDA, had awarded SNG001 with a fast track status.

But wait, there’s more news. On 13 January 2021, Synairgen reported that the first UK patient had been given the SNG001 treatment as part of its global Phase III trial for hospitalised Covid-19 patients. While there’s no guarantee the treatment being successful in the third phase, I’m optimistic on the prospects for Synairgen shares. If on the other hand, it didn’t pass the Phase III trial, I expect Synairgen shares to fall significantly.

So why have Synairgen shares rallied recently?

Well, it’s more positive news. I should highlight that the trial phases mentioned above are for hospitalised Covid-19 patients. And the results look promising.

In the past few weeks, Synairgen has announced that as part of its Phase II/III trails it’s now testing SNG001 on patients who are suffering with Covid-19 at home and don’t require hospitalisation. If this is successful, it’ll mean quicker treatment so this will reduce the need to transport infected patients and eliminate virus exposure to healthcare workers. This should be positive for Synairgen shares.

Would I buy Synairgen shares now?

It’s still early days for Synairgen. While the results so far look promising, I must highlight that this is a small company and there’s risks involved when investing. The risk for Synairgen to fail is greater than for its larger counterparts.

Once the global pandemic is over, I don’t think it’s end of the road for Synairgen. It could get snapped up by a large pharmaceutical competitor. The research conducted by Synairgen could prove useful for other respiratory diseases.

For these reasons, I’m comfortable with buying Synairgen shares within my diversified portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Does the BP share price scream ‘value’ after its earnings report?

The BP share price might not scream 'value', but the stock represents a cheaper alternative to several peers in the…

Read more »

Bronze bull and bear figurines
Investing Articles

1 dividend giant I’d buy over Lloyds shares right now

I sold my Lloyds shares recently and have used some of the proceeds to buy more of this high-yielding FTSE…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£11,000 in savings? Here’s how I’d aim to turn that into a £19,119 annual passive income!

Investing a relatively small amount in high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Investing Articles

Rolls Royce’s £4+ share price still looks a major bargain to me, so should I buy?

Rolls-Royce’s share price has shot up in the past year, but I think it’s still around 50% undervalued and is…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

A 10%+ yield but down 12%! Is this hidden FTSE 100 gem an unmissable passive income opportunity?

This FTSE 100 stock has one of the highest yields in the index, appears undervalued against its competitors, and looks…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Here’s how much I’d need to invest in Greggs shares for £100 in monthly passive income

A dividend rising 11% a year, a resilient business model, and strong future prospects put Greggs among the best UK…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Should investors buy IAG right now with the share price near 179p?

Recent positive share price trends may continue with this week’s upcoming release of first-quarter figures for IAG.

Read more »

Investing Articles

Up 6.3%, where will the Tesco share price go next?

The Tesco share price has been relatively steady of late, consolidating moderate gains over the past 12 months. Dr James…

Read more »